Evidence map›Paper›PMID 30709831›Full record

ArticleBMJ case reports2019

Long-lasting response to afatinib that persisted after treatment discontinuation in a case of

Yumie Yamanaka, Yoshitaka Seki, Takeo Ishikawa, Kazuyoshi Kuwano

Abstract readCase Reports
In one paragraph

Article in BMJ case reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yumie YamanakaDivision of Respirology, Department of Internal Medicine, The Jikei Daisan Hospital, Tokyo, Japan.
Yoshitaka SekiDivision of Respirology, Department of Internal Medicine, The Jikei Daisan Hospital, Tokyo, Japan.
Takeo IshikawaDivision of Respirology, Department of Internal Medicine, The Jikei Daisan Hospital, Tokyo, Japan.
Kazuyoshi KuwanoDivision of Respirology, Department of Internal Medicine, The Jikei University Hospital, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

It is unknown whether tyrosine kinase inhibitors targeting epidermal growth factor receptor (EGFR) can be discontinued in patients in whom

Indexed as

AfatinibAgedCarcinoma, Non-Small-Cell LungDisease-Free SurvivalErbB ReceptorsFemaleGenes, erbB-1HumansLiver NeoplasmsLung NeoplasmsMutationWithholding TreatmentAfatinibErbB Receptorschemotherapylung cancer (oncology)oncology

Identifiers

PMID30709831
PMCPMC6357919

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.